Protagonist Therapeutics, Inc (PTGX) financials: revenue, earnings and cash flow
Fiscal 2016–2025 · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$130M, a net margin of -282.8%; the best year in this period was 2024 with $275M.
Free cash flow was $56M in fiscal 2025 and positive in 3 of the 10 years shown.
The diluted share count rose 878% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $46M | $434M | $60M | $27M | $27M | $29M | $231000 | $31M | $20M | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$158M | $253M | -$94M | -$131M | -$126M | -$65M | -$81M | -$42M | -$38M | -$33M |
| Net income | -$130M | $275M | -$79M | -$127M | -$126M | -$66M | -$77M | -$39M | -$37M | -$37M |
| EPS (diluted) | $-2.05 | $4.23 | $-1.39 | $-2.60 | $-2.71 | $-1.92 | $-2.98 | $-1.74 | $-2.09 | $-5.80 |
| R&D | $159M | $138M | $120M | $126M | $126M | $75M | $65M | $59M | $46M | $26M |
| Revenue growth | −89.4% | +624.0% | +125.7% | −2.8% | −4.4% | +12293.1% | −99.2% | +54.1% | — | — |
Cash flow
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $58M | $184M | -$70M | -$108M | -$108M | -$72M | -$42M | -$50M | $4M | -$30M |
| Capital spending | -$2M | -$1M | -$609000 | -$795000 | -$1M | -$471000 | -$967000 | -$486000 | -$666000 | -$347000 |
| Free cash flow | $56M | $183M | -$71M | -$109M | -$109M | -$73M | -$42M | -$50M | $3M | -$30M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $46M | $38M | $29M | $24M | $16M | $8M | $8M | $7M | $4M | $2M |
Balance sheet
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | $567M | $419M | $342M | $237M | $327M | $306M | $133M | $129M | $106M | $21M |
| Debt | $10M | $11M | $1M | $4M | $6M | $6M | $17M | — | — | — |
| Equity | $615M | $675M | $337M | $216M | $300M | $280M | $80M | $113M | $121M | $88M |
| Total assets | $668M | $745M | $358M | $248M | $348M | $324M | $155M | $139M | $164M | $94M |
| Shares (diluted) | 64M | 65M | 57M | 49M | 46M | 34M | 26M | 22M | 18M | 7M |
Margins and returns
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | -343.6% | 58.2% | -156.1% | -494.2% | -460.0% | -225.4% | -34857.6% | -136.7% | -188.9% | — |
| Net margin | -282.8% | 63.3% | -131.6% | -479.3% | -458.9% | -231.1% | -33414.3% | -125.9% | -184.2% | — |
| FCF margin | 121.9% | 42.1% | -118.1% | -409.8% | -398.3% | -254.8% | -18395.7% | -163.1% | 16.0% | — |
| ROIC | -20.0% | 36.3% | -27.7% | -59.9% | -41.1% | -17.8% | -82.3% | -36.8% | -31.4% | -37.3% |
| ROE | -21.2% | 40.8% | -23.4% | -59.1% | -41.9% | -23.7% | -96.5% | -34.6% | -30.6% | -42.5% |
Frequently asked questions
What is Protagonist Therapeutics’s annual revenue?
$46M in fiscal 2025.
How much profit does Protagonist Therapeutics make?
Net income was -$130M in fiscal 2025 (net margin -282.8%).
Is Protagonist Therapeutics’s revenue growing?
No: revenue fell 89.4% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.